INCPF 财务： InnoCare Pharma Limited AI 分析

主页

股票

INCPF

财务数据

INCPF 财务

InnoCare Pharma Limited

$1.55

截至今日：Mar 26, 15:32:00 GMT-4

概述预测收益股息财务数据

关键数据

前收盘价

$1.55

开盘价

$2.05

当日区间

$1.55 - $2.05

52周范围

$1.55 - $3.26

交易量

1.0K

平均成交量

股息收益率

每股收益（TTM）

-0.02

市值

$2.3B

什么是 INNOCARE PHARMA LTD？

InnoCare Pharma Ltd is a CN-based company operating in Biotechnology industry. The company is headquartered in Beijing, Beijing and currently employs 1,146 full-time employees. The company went IPO on 2020-03-23. InnoCare Pharma Ltd is a China-based company mainly engaged in the research and development, production and commercialization of biopharmaceuticals. The firm focuses on areas with unmet clinical needs, such as oncology and autoimmune diseases. The firm's primary product pipeline includes Orelabrutinib, Tafasitamab, ICP-490, ICP-B02, ICP-248, ICP-B05, ICP-332, ICP-488, ICP-192, ICP-723, ICP-033 and ICP-189, and others. Its products are mainly used to treat hematological tumors, solid tumors and autoimmune diseases. The firm is also developing products for the treatment of autoimmune diseases caused by abnormal T cell function. The firm conducts its businesses in domestic and overseas markets.

功能特性

资源

市场

收入

资产负债表

现金流量

年度

季度性

INCPF 收入

以百万美元为单位的财务数据。财年为2月至次年1月。

Breakdown	TTM	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020
营收	1,427	1,009	738	625	1,043	1
营收同比增长 (YoY)	105%	37%	18%	-40%	104,200%	--
营收成本	185	138	128	143	65	0
毛利润	1,241	871	610	482	977	1
销售、一般及管理费用	704	584	539	602	429	152
研发	875	737	691	596	699	391
营业费用	1,537	1,392	1,282	1,212	1,143	495
其他非经营性收入 (费用)	-1	-1	6	0	1	-1
税前利润	-231	-452	-644	-893	-20	-391
所得税费用	8	0	1	0	46	0
净利润	-229	-440	-631	-886	-64	-391
净利润增长	-17%	-30%	-28.99%	1,284%	-84%	--
稀释后流通股数	1,821.97	1,694.74	1,706.11	1,764.32	1,764.32	1,764.32
股份同比变动 (YoY)	-4%	-1%	-3%	0%	0%	--
每股收益 (摊薄)	-0.12	-0.26	-0.37	-0.5	-0.03	-0.22
每股收益增长率	-14%	-30%	-26%	1,273%	-84%	--
自由现金流	-162	-443	-920	-860	-4	-526
每股自由现金流	--	--	--	--	--	--
毛利率	86.96%	86.32%	82.65%	77.12%	93.67%	100%
营业利润率	-20.74%	-51.63%	-91.05%	-116.8%	-15.81%	-49,400%
净利率	-16.04%	-43.6%	-85.5%	-141.76%	-6.13%	-39,100%
自由现金流利润率	-11.35%	-43.9%	-124.66%	-137.6%	-0.38%	-52,600%
EBITDA	--	-424	-585	-660	-123	-455
EBITDA 利润率	--	-42.02%	-79.26%	-105.6%	-11.79%	-45,500%
EBITDA 中的折旧与摊销	--	97	87	70	42	39
EBIT	-296	-521	-672	-730	-165	-494
EBIT 利润率	-20.74%	-51.63%	-91.05%	-116.8%	-15.81%	-49,400%
有效税率	-3.46%	0%	-0.15%	0%	-229.99%	0%

Follow-Up Questions

InnoCare Pharma Limited 的关键财务报表是什么？



根据最新的财务报表（Form-10K），InnoCare Pharma Limited 的总资产为 $9,407，净损失为 $-440

INCPF 的关键财务比率是什么？



InnoCare Pharma Limited 的流动比率是 3.5，净利 margin 为 -43.6，每股销售为 $0.59。

InnoCare Pharma Limited 的收入按细分市场或地理位置如何划分？



InnoCare Pharma Limited 最大收入来源是 Biopharmaceutical Research and Development, Manufacturing, Commercialization and Services，在最近的收益报告中收入为 738,537,047。就地区而言， China 是 InnoCare Pharma Limited 的主要市场，收入为 673,133,902。

InnoCare Pharma Limited 是否盈利？



不，根据最新的财务报表，InnoCare Pharma Limited 的净损失为 $-440

InnoCare Pharma Limited 有负债吗？



是的，InnoCare Pharma Limited 的负债为 2,682

InnoCare Pharma Limited 的流通股有多少？



InnoCare Pharma Limited 的总流通股为 1,762

InnoCare Pharma Limited (INCPF) 财务

INCPF 股价走势图